16
Participants
Start Date
November 27, 2017
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2025
Pembrolizumab
Pembrolizumab is a type of antibody that inhibits the cancer cell growth
Dabrafenib
Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
Trametinib
Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
Beth Israel Deaconess Medical Center, Boston
Massachusetts general Hospital, Boston
Merck Sharp & Dohme LLC
INDUSTRY
Massachusetts General Hospital
OTHER